Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 2 February 2018, 16:15 HKT/SGT
Share:
    

Source: Vetter Pharma International GmbH
Vetter invites South Korea's pharma and biotech community to meet company management

SONGDO and RAVENSBURG, Feb 2, 2018 - (Media OutReach) - In an event at its new branch office attended by key customers and business associates, Vetter's senior management representatives presented the company's service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. In addition, attendees were introduced to Mr. Michael Yi who will manage the office in his role as Business Development Manager for Vetter Pharma International GmbH, South Korea. Mr. Yi, who is based in Songdo, has pharmaceutical experience in responsible business development roles at several companies. He reports to Ms. Chervee Ho in her role as Director Key Account Management Asia Pacific.

During Vetter's customer event in the new branch office: Jong Hyun Kim, Director Supply Chain Management Department at Celltrion, Inc. (3rd from left) with Vetter's Chervee Ho, Peter Soelkner, Michael Yi and Oskar Gold (from left to right). (Picture source: Vetter Pharma International GmbH)

A rapidly growing local economy, combined with a regulatory environment conducive to the industry is a strong incentive for doing business in the country. And, because the population is aging rapidly with corresponding needs for adequate medication, South Korea demonstrates strong commitment to the pharmaceutical market through investing and supporting campaigns in R&D that contribute to innovative healthcare products. With its branch office, Vetter is well positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

"As a leading contract and development manufacturing organization in prefilled drug delivery systems with a vast amount of experience in business development, we are well aware that being physically close to our customers and their ongoing projects is one of the keys to good client relationships," said Vetter Managing Director Peter Soelkner. "Our event today acts as an additional signal of our strategy to build on our local presence and activities in this market," highlights Oskar Gold, Vetter's Senior Vice President Key Account Management, Marketing/Corporate Communications and Customer Project Management.

"Vetter's entry into the Korean pharmaceutical market represents an important recognition of the progress our nation has made in this segment," said Javier Camposano, Celltrion's Managing Director for Drug Product. "South Korean companies such as ours are in need of the services Vetter offers, to help us bring our innovative products to local and global markets. With its long history of qualitative resources, combined with its state-of-the art technology, Vetter can support us in competing on a level playing field and achieving our goals on a global scale. We wish Vetter a successful future in Korea."

Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center. https://www.vetter-pharma.com/en/news-events/download-center

About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. The company has long-term experience offering services ranging from early development support including clinical manufacturing, to commercial supply and various packaging solutions for vials, syringes and cartridges. Vetter's customers range from small and midsize to the world's top 20 pharmaceutical and biotech companies. As a leading solution provider, the CDMO recognizes its responsibility in supporting the needs of its customers in developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Learn more about Vetter at www.vetter-pharma.com.

Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com


Topic: Press release summary
Source: Vetter Pharma International GmbH


http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
HKTDC Home InStyle, Fashion InStyle open today  
Apr 20, 2024 19:00 HKT/SGT
POWERSCHOOL HOLDINGS, INC. (PWSC): Kaplan Fox & Kilsheimer LLP Investigates POWERSCHOOL and Encourages Investors to Contact the Firm  
Apr 20, 2024 11:16 HKT/SGT
JABIL (JBL): JABIL DISCLOSES INVESTIGATION AND PLACES CEO ON PAID LEAVE - Kaplan Fox & Kilsheimer LLP Investigates and Encourages Investors to Contact the Firm  
Apr 20, 2024 10:00 HKT/SGT
Phish Live at Sphere: Moment Factory Harnesses Sphere's Next-Generation Technologies to Reimagine Concert Experience  
Apr 20, 2024 09:00 HKT/SGT
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25  
Apr 20, 2024 01:00 HKT/SGT
Brawijaya University researcher develops honey-processing tech  
Apr 19, 2024 23:00 HKT/SGT
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations  
Apr 19, 2024 20:03 HKT/SGT
GLOBE LIFE (GL): Kaplan Fox & Kilsheimer LLP Investigates GLOBE LIFE and Encourages Investors to Contact the Firm  
Apr 19, 2024 20:00 HKT/SGT
SMC Announces Marketing Agreement with Plato Technologies. Inc.  
Apr 19, 2024 16:03 HKT/SGT
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe  
Friday, April 19, 2024 12:50:00 PM
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: